Intravenous Allogeneic Mesenchymal Stem Cells for Nonischemic Cardiomyopathy Safety and Efficacy Results of a Phase II-A Randomized Trial

被引:141
作者
Butler, Javed [1 ]
Epstein, Stephen E. [2 ]
Greene, Stephen J. [3 ]
Quyyumi, Arshed A. [4 ]
Sikora, Sergey [5 ]
Kim, Raymond J. [3 ]
Anderson, Allen S. [6 ]
Wilcox, Jane E. [6 ]
Tankovich, Nikolai I. [7 ]
Lipinski, Michael J. [2 ]
Ko, Yi-An [8 ]
Margulies, Kenneth B. [9 ]
Cole, Robert T. [4 ]
Skopicki, Hal A. [1 ]
Gheorghiade, Mihai [10 ]
机构
[1] SUNY Stony Brook, Dept Med, Div Cardiol, Stony Brook, NY 11794 USA
[2] MedStar Washington Hosp Ctr, MedStar Heart & Vasc Inst, Washington, DC USA
[3] Duke Univ, Med Ctr, Dept Med, Div Cardiol, Durham, NC 27710 USA
[4] Emory Univ, Dept Med, Div Cardiol, Atlanta, GA 30322 USA
[5] CardioCell LLC, San Diego, CA USA
[6] Northwestern Univ, Dept Med, Div Cardiol, Feinberg Sch Med, Chicago, IL 60611 USA
[7] Stemedica Cell Technol Inc, San Diego, CA USA
[8] Emory Univ, Dept Biostat & Bioinformat, Atlanta, GA 30322 USA
[9] Univ Penn, Dept Med, Div Cardiol, Perelman Sch Med, Philadelphia, PA 19104 USA
[10] Northwestern Univ, Ctr Cardiovasc Innovat, Feinberg Sch Med, Chicago, IL 60611 USA
关键词
cardiomyopathy; clinical trial; heart failure; nonischemic; stem cells; viable myocardium; HOSPITALIZED HEART-FAILURE; 6-MINUTE WALK TEST; EJECTION FRACTION; DRUG DEVELOPMENT; DYSFUNCTION; THERAPY; HEALTH; DEATH;
D O I
10.1161/CIRCRESAHA.116.309717
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Rationale: Potential benefits of mesenchymal stem cell (MSC) therapy in heart failure may be related to paracrine properties and systemic effects, including anti-inflammatory activities. If this hypothesis is valid, intravenous administration of MSCs should improve outcomes in heart failure, an entity in which excessive chronic inflammation may play a pivotal role. Objective: To assess the safety and preliminary efficacy of intravenously administered ischemia-tolerant MSCs (itMSCs) in patients with nonischemic cardiomyopathy. Methods and Results: This was a single-blind, placebo-controlled, crossover, randomized phase II-a trial of nonischemic cardiomyopathy patients with left ventricular ejection fraction <= 40% and absent hyperenhancement on cardiac magnetic resonance imaging. Patients were randomized to intravenously administered itMSCs (1.5x10(6) cells/kg) or placebo; at 90 days, each group received the alternative treatment. Overall, 22 patients were randomized to itMSC (n=10) and placebo (n=12) at baseline. After crossover, data were available for 22 itMSC patients. No major differences in death, hospitalization, or serious adverse events were noted between the 2 treatments. Change from baseline in left ventricular ejection fraction and ventricular volumes was not significantly different between therapies. Compared with placebo, itMSC therapy increased 6-minute walk distance (+36.47 m, 95% confidence interval 5.98-66.97; P=0.02) and improved Kansas City Cardiomyopathy clinical summary (+5.22, 95% confidence interval 0.70-9.74; P=0.02) and functional status scores (+5.65, 95% confidence interval -0.11 to 11.41; P=0.06). The data demonstrated MSC-induced immunomodulatory effects, the magnitude of which correlated with improvement in left ventricular ejection fraction. Conclusions: In this pilot study of patients with nonischemic cardiomyopathy, itMSC therapy was safe, caused immunomodulatory effects, and was associated with improvements in health status and functional capacity.
引用
收藏
页码:332 / +
页数:12
相关论文
共 22 条
[11]
Immunological Aspects of Allogeneic Mesenchymal Stem Cell Therapies [J].
Griffin, Matthew D. ;
Ritter, Thomas ;
Mahon, Bernard P. .
HUMAN GENE THERAPY, 2010, 21 (12) :1641-1655
[12]
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of Intravenous Adult Human Mesenchymal Stem Cells (Prochymal) After Acute Myocardial Infarction [J].
Hare, Joshua M. ;
Traverse, Jay H. ;
Henry, Timothy D. ;
Dib, Nabil ;
Strumpf, Robert K. ;
Schulman, Steven P. ;
Gerstenblith, Gary ;
DeMaria, Anthony N. ;
Denktas, Ali E. ;
Gammon, Roger S. ;
Hermiller, James B., Jr. ;
Reisman, Mark A. ;
Schaer, Gary L. ;
Sherman, Warren .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 54 (24) :2277-2286
[13]
Health status identifies heart failure outpatients at risk for hospitalization or death [J].
Heidenreich, PA ;
Spertus, JA ;
Jones, PG ;
Weintraub, WS ;
Rumsfeld, JS ;
Rathore, SS ;
Peterson, ED ;
Masoudi, FA ;
Krumholz, HM ;
Havranek, EP ;
Conard, MW ;
Williams, RE .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (04) :752-756
[14]
Mechanisms Contributing to the Progression of Ischemic and Nonischemic Dilated Cardiomyopathy Possible Modulating Effects of Paracrine Activities of Stem Cells [J].
Kelkar, Anita A. ;
Butler, Javed ;
Schelbert, Erik B. ;
Greene, Stephen J. ;
Quyyumi, Arshed A. ;
Bonow, Robert O. ;
Cohen, Ira ;
Gheorghiade, Mihai ;
Lipinski, Michael J. ;
Sun, Wei ;
Luger, Dror ;
Epstein, Stephen E. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 66 (18) :2038-2047
[15]
The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. [J].
Kim, RJ ;
Wu, E ;
Rafael, A ;
Chen, EL ;
Parker, MA ;
Simonetti, O ;
Klocke, FJ ;
Bonow, RO ;
Judd, RM .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (20) :1445-1453
[16]
Little R. J., 2019, Statistical analysis with missing data, V793
[17]
Bone marrow-derived mesenchymal stem cells for the treatment of heart failure [J].
Narita, Takuya ;
Suzuki, Ken .
HEART FAILURE REVIEWS, 2015, 20 (01) :53-68
[18]
Cell Therapy for Heart Failure A Comprehensive Overview of Experimental and Clinical Studies, Current Challenges, and Future Directions [J].
Sanganalmath, Santosh K. ;
Bolli, Roberto .
CIRCULATION RESEARCH, 2013, 113 (06) :810-834
[19]
The disconnect between phase II and phase III trials of drugs for heart failure [J].
Vaduganathan, Muthiah ;
Greene, Stephen J. ;
Ambrosy, Andrew P. ;
Gheorghiade, Mihai ;
Butler, Javed .
NATURE REVIEWS CARDIOLOGY, 2013, 10 (02) :85-97
[20]
High targeted migration of human mesenchymal stem cells grown in hypoxia is associated with enhanced activation of RhoA [J].
Vertelov, Grigory ;
Kharazi, Ludmila ;
Muralidhar, M. G. ;
Sanati, Givon ;
Tankovich, Timothy ;
Kharazi, Alex .
STEM CELL RESEARCH & THERAPY, 2013, 4 :5